Hence then, the article about formosa pharmaceuticals and aimmax therapeutics announce the nda submission to the us fda for app13007 for the treatment of post operative inflammation and pain following ocular surgery was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery )
Also on site :
- Timothee Chalamet Shows Subtle Support for Girlfriend Kylie Jenner
- From collapse fears to resilience: How Russia reshaped its economy by the end of 2025
- Russian MOD shows map of Ukrainian drone attack on Putin’s residence